Market Overview

UPDATE: Ascendiant Capital Markets Upgrades POZEN to Strong Buy, Reiterates $8.25 PT

Related POZN
Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops
POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals, $350 Million Capital Commitment from Deerfield-Led Syndicate

In a report published Friday, Ascendiant Capital Markets upgraded its rating on POZEN (NASDAQ: POZN) to Strong Buy, and reiterated its $8.25 price target.

Ascendiant Capital noted, “We believe that the focus for investors should remain on the Company's efforts to complete the work necessary to file an NDA with the FDA for its PA product. The Company's PA product represents the combined delivery of immediate-release omeprazole (40mg) and delayed-release aspirin (either 325mg or 81 mg). PA has the potential to offer possible protection against a second heart attack or stroke without the increase in gastrointestinal toxicity associated with aspirin alone. Management reiterated that it remains on track to submit an NDA for both PA32540 and PA8140 in the first half of next year. Pozen expects to complete a required pharmacokinetic study that demonstrates the bioequivalence of PA8140 against the RLD, EC-Ecotrin 81 mg by the end of this year. The gating item for the NDA submission will be the sufficiency of the Company's Chemistry, Manufacturing, and Controls (CMC) process for PA8140 at the time of filing. Although stability data for the product is required out to 12 months, the Company's plan is provide supplemental data to its NDA filing, once the 12 month stability data is obtained.”

POZEN closed on Thursday at $5.13.

Latest Ratings for POZN

Feb 2015Chardan CapitalInitiates Coverage onBuy
Aug 2014Ascendiant CapitalUpgradesHoldBuy
Apr 2013JefferiesTerminatesHold

View More Analyst Ratings for POZN
View the Latest Analyst Ratings

Posted-In: Ascendiant Capital MarketsAnalyst Color Upgrades Analyst Ratings


Related Articles (POZN)

View Comments and Join the Discussion!